Biotech is “hot” and M&A deals are likely to be an ongoing feature of the industry
Whilst we are probably waiting for the biotech IPO cycle to bottom out in Europe, secondary financings have been going strong…
Scaling up a Company to $10bn-$20bn
Europe is missing many companies scaled up to this market cap bracket, partly because any pretenders to the title have been acquired…
